SCHEMBL22254341

SCHEMBL22254341

CC(C)(C)OC(=O)NC1CCN(Cc2ccc(-n3ccc(NC(=O)n4ccnc4)nc3=O)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.40
▸ PARP2 Q9UGN5 1/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ JAK1 P23458 1/20 0.39
▸ TP53 P04637 2/20 0.38
▸ MCHR1 Q99705 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ NAMPT P43490 2/20 0.37
▸ NSD2 O96028 1/20 0.37
▸ USP14 P54578 1/20 0.37
▸ KCNA3 P22001 1/20 0.37
▸ KCNH2 Q12809 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ DRD2 P14416 1/20 0.35
▸ DRD4 P21917 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ AAK1 Q2M2I8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22255076 0.93 KCNA3 (0.40) PARP1PARP2AKT1TP53NAMPT
SCHEMBL30400320 0.89 NEK1 (0.40) JAK1TP53NAMPTDRD2
SCHEMBL30400154 0.89 NAMPT (0.39) PARP1JAK1NAMPTKCNA3
SCHEMBL30276488 0.88 JAK1 (0.37) JAK1MCHR1NAMPTDRD2KMT2A
SCHEMBL22234102 0.88 DRD4 (0.41) MCHR1CYP3A4DRD2DRD4DRD3
SCHEMBL30398640 0.88 NAMPT (0.35) PARP1AKT1JAK1NAMPTUSP14
SCHEMBL30400922 0.87 AKT1 (0.40) PARP1PARP2AKT1JAK1TP53
SCHEMBL30401079 0.87 MCHR1 (0.44) PARP1PARP2AKT1JAK1TP53
SCHEMBL30401127 0.85 PARP1 (0.42) PARP1PARP2AKT1JAK1TP53
SCHEMBL30401137 0.85 GPR119 (0.34) PARP1JAK1NAMPTDRD2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 — — US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 — — US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 — — US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 — — US disclosed
WO-2020150385-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 PARP1 468/4885PARP2 730/4885AKT1 2475/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 PARP1 468/4885PARP2 730/4885AKT1 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback